908 Devices (MASS) EBITDA Yield: History & Chart

908 Devices Inc.(MASS)

Medical - Specialties · Burlington, MA

$12.57-0.23 (-1.79%)

Delayed quote: Oct 6, 2026, 11:45 AM EDT

About 908 Devices Inc.

908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Burlington, Massachusetts.

Burlington, MA

172 employees

www.908devices.com

Healthcare / Medical - Specialties

Sector: Healthcare
Industry: Medical - Specialties
CEO: Kevin J. Knopp

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
908 Devices Inc. (MASS)	$515.72M	N/A	N/A	N/A	N/A
Allogene Therapeutics, Inc. (ALLO)vs ›	$510.83M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$523.14M	N/A	N/A	N/A	N/A
Crescent Biopharma, Inc. (CBIO)vs ›	$523.17M	N/A	N/A	N/A	N/A
Monopar Therapeutics Inc. (MNPR)vs ›	$522.07M	N/A	N/A	N/A	N/A
Oculis Holding AG (OCS)vs ›	$501.67M	N/A	N/A	N/A	N/A
Evolus, Inc. (EOLS)vs ›	$493.91M	N/A	N/A	N/A	N/A
Phathom Pharmaceuticals, Inc. (PHAT)vs ›	$540.09M	N/A	N/A	N/A	N/A
Puma Biotechnology, Inc. (PBYI)vs ›	$489.14M	9.49%	13.75%	18.95%	18.84%
Immix Biopharma, Inc. (IMMX)vs ›	$539.42M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

908 Devices Inc. (MASS)

$515.72M

N/A

Allogene Therapeutics, Inc. (ALLO)vs ›

$510.83M

N/A

Altimmune, Inc. (ALT)vs ›

$523.14M

N/A

Crescent Biopharma, Inc. (CBIO)vs ›

$523.17M

N/A

Monopar Therapeutics Inc. (MNPR)vs ›

$522.07M

N/A

Oculis Holding AG (OCS)vs ›

$501.67M

N/A

Evolus, Inc. (EOLS)vs ›

$493.91M

N/A

Phathom Pharmaceuticals, Inc. (PHAT)vs ›

$540.09M

N/A

Puma Biotechnology, Inc. (PBYI)vs ›

$489.14M

9.49%

13.75%

18.95%

18.84%

Immix Biopharma, Inc. (IMMX)vs ›

$539.42M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

MASS EBITDA Yield Metrics

MASS Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics